Early Outpatient Follow-up and 30-day Outcomes in Patients Hospitalized with Cirrhosis
Overview
Affiliations
Unlabelled: Preventing readmission has been the focus of numerous quality improvement efforts across many conditions. Early outpatient follow-up has been proposed as the best mechanism for reducing readmissions. The extent to which early outpatient follow-up averts readmission or improves outcomes in cirrhosis is not known. We evaluated the relationship between early outpatient follow-up and short-term readmission and mortality in patients with cirrhosis. We conducted a retrospective cohort study of patients with cirrhosis who were hospitalized with a liver-related diagnosis and discharged to home from 122 Veterans Administration hospitals between 2010 and 2013. We defined early follow-up as an outpatient visit with a clinician within 7 days after discharge. We propensity matched patients who received early visit with those who did not have any visit and examined the associations between early follow-up and all-cause readmission and mortality within 8-30 days after discharge. Of 25,217 patients hospitalized with cirrhosis, 8,123 (32.2%) had an early follow-up visit within 7 days of discharge. A total of 3,492 (13.8%) patients were readmitted and 1,185 (4.6%) died between 8 and 30 days after discharge. In the propensity-matched sample (N = 16,238), patients with early outpatient follow-up visit had a slightly higher risk of readmission (15.3% vs. 13.8%; hazard ratio [HR] =1.10; 95% confidence interval [CI] = 1.02-1.19), but significantly lower risk of mortality (3.2% vs. 5.2%; HR = 0.60; 95% CI = 0.51-0.70) than those without early visit. The findings persisted in several subgroup and sensitivity analyses.
Conclusions: Early outpatient follow-up after discharge was associated with a small increase in readmissions but lower overall mortality in patients with cirrhosis. Transitional care may be effective in improving short-term outcomes in patients with cirrhosis, but readmission performance measures would miss this effect. (Hepatology 2016;64:569-581).
Bai J, Manokaran T, Meldrum L, Tang K J Gen Intern Med. 2025; .
PMID: 39843668 DOI: 10.1007/s11606-024-09340-2.
Schechter M, Widman L, Wester A, Shang Y, Stal P, Fortune B Aliment Pharmacol Ther. 2024; 61(1):109-121.
PMID: 39354777 PMC: 11636062. DOI: 10.1111/apt.18309.
Favre-Bulle T, Moradpour D, Marques-Vidal P, Vaucher J BMJ Open. 2024; 14(8):e081822.
PMID: 39181561 PMC: 11344505. DOI: 10.1136/bmjopen-2023-081822.
Design, implementation, and impact of a cirrhosis-specific remote patient monitoring program.
Penrice D, Hara K, Sordi-Chara B, Kezer C, Schmidt K, Kassmeyer B Hepatol Commun. 2024; 8(8).
PMID: 39037370 PMC: 11265784. DOI: 10.1097/HC9.0000000000000498.
Li N, Xu M, Liu S, Yu M, Ruan C J Int Med Res. 2024; 52(1):3000605231223087.
PMID: 38258740 PMC: 10807325. DOI: 10.1177/03000605231223087.